Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Urocanic acid - Herantis Pharma

Drug Profile

Urocanic acid - Herantis Pharma

Alternative Names: Ci-UCA Emulsion Cream; Cis-UCA; Cis-UCA Eye Drops; ProtoCure; UCA-001; UCA-002

Latest Information Update: 28 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioCis Pharma
  • Developer Herantis Pharma
  • Class Acrylates; Antineoplastics; Imidazoles; Immunotherapies; Skin disorder therapies; Small molecules
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Atopic dermatitis; Dry eyes

Highest Development Phases

  • Phase II Dry eyes
  • Suspended Atopic dermatitis
  • No development reported Bladder cancer; Interstitial cystitis
  • Discontinued Plaque psoriasis

Most Recent Events

  • 28 Feb 2019 No recent reports of development identified for phase-I development in Dry-eyes(In volunteers) in Finland (Ophthalmic, Drops)
  • 07 Feb 2017 Phase-II development for Dry eyes is ongoing in USA (Ophthalmic, drops)
  • 12 Oct 2015 Urocanic acid - Herantis Pharma is available for licensing-http://herantis.com/wp-content/uploads/2015/09/Herantis_NLS_2015.pdf
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top